Your browser is no longer supported. Please, upgrade your browser.
Settings
RGNX Regenxbio Inc. daily Stock Chart
RGNX [NASD]
Regenxbio Inc.
Index- P/E- EPS (ttm)-2.71 Insider Own0.70% Shs Outstand39.36M Perf Week-9.36%
Market Cap1.07B Forward P/E- EPS next Y-3.08 Insider Trans-54.91% Shs Float25.90M Perf Month-9.52%
Income-76.80M PEG- EPS next Q-0.79 Inst Own69.70% Short Float5.13% Perf Quarter-17.50%
Sales10.00M P/S106.67 EPS this Y-146.10% Inst Trans0.12% Short Ratio3.44 Perf Half Y43.39%
Book/sh6.29 P/B4.31 EPS next Y-13.20% ROA-37.00% Target Price43.83 Perf Year35.50%
Cash/sh4.24 P/C6.40 EPS next 5Y-7.10% ROE-39.30% 52W Range16.30 - 36.45 Perf YTD-18.50%
Dividend- P/FCF- EPS past 5Y- ROI-40.10% 52W High-25.65% Beta-
Dividend %- Quick Ratio12.80 Sales past 5Y- Gross Margin75.90% 52W Low66.26% ATR1.96
Employees107 Current Ratio12.80 Sales Q/Q968.80% Oper. Margin- RSI (14)42.09 Volatility5.08% 6.34%
OptionableYes Debt/Eq0.00 EPS Q/Q2.40% Profit Margin- Rel Volume0.63 Prev Close27.55
ShortableYes LT Debt/Eq0.00 EarningsFeb 07 AMC Payout- Avg Volume386.41K Price27.10
Recom1.80 SMA20-12.78% SMA50-7.83% SMA20011.20% Volume243,146 Change-1.63%
Nov-09-17Resumed Morgan Stanley Overweight $34
Nov-09-17Reiterated Chardan Capital Markets Buy $75 → $85
Oct-12-17Initiated Raymond James Outperform $39
Aug-17-17Initiated Evercore ISI Outperform $25
Aug-09-17Reiterated Chardan Capital Markets Buy $50 → $55
Apr-11-17Reiterated Chardan Capital Markets Buy $35 → $50
Oct-20-15Initiated Chardan Capital Markets Buy $33
Oct-13-15Initiated Morgan Stanley Overweight
Oct-12-15Initiated Piper Jaffray Overweight $36
Oct-12-15Initiated BofA/Merrill Buy $29
Jan-19-18 07:50AM  Consolidated Research: 2018 Summary Expectations for REGENXBIO, Rexahn Pharmaceuticals, QuinStreet, NewMarket, Stock Yards, and United States Lime & Minerals Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-11-18 03:00AM  Stocks With Rising Relative Price Strength: Regenxbio Investor's Business Daily +6.79%
Jan-08-18 09:31AM  [$$] Gene-Therapy Update: Mixed Results Don't Dim Hopes Barrons.com
08:00AM  REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy GlobeNewswire
Jan-05-18 12:59PM  Here's Why Regenxbio Dropped as Much as 17.6% Today Motley Fool -20.88%
Jan-04-18 04:05PM  REGENXBIO Provides Year-End 2017 Corporate Update GlobeNewswire
Jan-02-18 12:01PM  Edited Transcript of RGNX earnings conference call or presentation 8-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Dec-28-17 12:39PM  ETFs with exposure to REGENXBIO, Inc. : December 28, 2017 Capital Cube
Dec-27-17 08:53AM  REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-21-17 03:00AM  Regenxbio Shows Rising Price Performance With Jump To 93 RS Rating Investor's Business Daily
Dec-20-17 07:22AM  REGENXBIO, Inc. is trading above its 50 day moving average : RGNX-US : December 20, 2017 Capital Cube
Dec-19-17 07:00AM  REGENXBIO Announces IND Active for Phase I/II Trial of RGX-121 to Treat Mucopolysaccharidosis Type II GlobeNewswire
Dec-08-17 07:15AM  REGENXBIO, Inc. breached its 50 day moving average in a Bullish Manner : RGNX-US : December 8, 2017 Capital Cube
Dec-07-17 03:00AM  Regenxbio Joins Rank Of Stocks With RS Ratings Over 90 Investor's Business Daily
Nov-22-17 07:00AM  REGENXBIO to Present at Upcoming Investor Conferences GlobeNewswire
Nov-08-17 05:33PM  Regenxbio reports 3Q loss Associated Press
04:05PM  REGENXBIO Reports Third Quarter 2017 Financial Results and Recent Operational Highlights GlobeNewswire
Nov-06-17 09:54AM  What's in the Cards for Repros (RPRX) This Earnings Season? Zacks
Nov-02-17 08:31AM  REGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : November 2, 2017 Capital Cube
Nov-01-17 07:00AM  REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2017 Financial Results and Recent Operational Highlights GlobeNewswire -8.18%
Oct-30-17 12:12PM  ETFs with exposure to REGENXBIO, Inc. : October 30, 2017 Capital Cube
Oct-20-17 10:24AM  ETFs with exposure to REGENXBIO, Inc. : October 20, 2017 Capital Cube
Oct-13-17 12:31PM  Gene Therapies: A Foot in the Door Barrons.com
Oct-09-17 11:59AM  ETFs with exposure to REGENXBIO, Inc. : October 9, 2017 Capital Cube
Oct-06-17 09:09AM  REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Capital Cube
Oct-03-17 02:35PM  After bidding war, North Bay drug maker snags gene therapy company for $151 million American City Business Journals
12:20PM  After bidding war, Cambridge gene therapy firm Dimension accepts $151M buyout American City Business Journals
09:58AM  Dimension Shares Rise On Sale to Ultragenyx - Biotech Movers TheStreet.com
08:30AM  Ultragenyx to Acquire Dimension Therapeutics GlobeNewswire
07:00AM  REGENXBIO to Present at Upcoming Investor Conferences GlobeNewswire
Oct-02-17 02:25PM  RegenxBio declines to push forward on planned acquisition American City Business Journals
08:30AM  REGENXBIO Responds to Notification of a Superior Proposal Under Its Merger Agreement With Dimension Therapeutics GlobeNewswire
08:00AM  Dimension Board Determines that Ultragenyxs Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a Superior Proposal GlobeNewswire
Sep-29-17 06:00AM  8 Stocks for the Next Gene Revolution Investopedia
Sep-28-17 06:21PM  Edited Transcript of RGNX earnings conference call or presentation 8-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Sep-25-17 09:57AM  Gene Therapy: A Big Week for Many Names Barrons.com +9.56%
12:01AM  [$$] Gene Therapy Is Nearing a Major Breakthrough Barrons.com
Sep-20-17 07:00AM  REGENXBIO Announces Completion of Dosing of First Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD GlobeNewswire
Sep-19-17 08:00AM  Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a Superior Proposal GlobeNewswire
Sep-18-17 03:10PM  Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx GlobeNewswire +5.49%
01:18PM  UPDATED: Dimension Therapeutics shares surge 38% on Ultragenyx bid MarketWatch
09:35AM  Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers TheStreet.com
Sep-06-17 08:46AM  Regenxbio (RGNX) in Focus: Stock Moves 9.5% Higher Zacks
Aug-31-17 06:23PM  SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Dimension Therapeutics, Inc. - DMTX PR Newswire +7.82%
07:00AM  REGENXBIO to Present at Upcoming Investor Conferences GlobeNewswire
Aug-29-17 11:45AM  DIMENSION THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dimension Therapeutics, Inc. PR Newswire
Aug-25-17 12:40PM  Rockville biotech buys Cambridge gene therapy firm for $86M American City Business Journals
11:25AM  Cambridge gene therapy firm Dimension Therapeutics to be acquired American City Business Journals
08:00AM  REGENXBIO to Acquire Dimension Therapeutics GlobeNewswire
Aug-10-17 08:20AM  REGENXBIO, Inc. breached its 50 day moving average in a Bullish Manner : RGNX-US : August 10, 2017 Capital Cube
12:33AM  Regenxbio reports 2Q loss Associated Press
Aug-08-17 04:05PM  REGENXBIO Reports Second Quarter 2017 Financial Results and Recent Operational Highlights GlobeNewswire
Aug-01-17 07:24PM  REGENXBIO, Inc. Value Analysis (NASDAQ:RGNX) : August 1, 2017 Capital Cube
04:05PM  REGENXBIO to Host Conference Call on August 8 to Discuss Second Quarter 2017 Financial Results and Recent Operational Highlights GlobeNewswire
Jul-19-17 09:08AM  REGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : July 19, 2017 Capital Cube
Jul-06-17 04:05PM  REGENXBIO to Participate in the Piper Jaffray GenomeRx Symposium GlobeNewswire
Jun-21-17 08:05AM  REGENXBIO, Inc. breached its 50 day moving average in a Bullish Manner : RGNX-US : June 21, 2017 Capital Cube
Jun-15-17 03:08PM  ETFs with exposure to REGENXBIO, Inc. : June 15, 2017 Capital Cube
Jun-08-17 08:07AM  REGENXBIO, Inc. breached its 50 day moving average in a Bullish Manner : RGNX-US : June 8, 2017 Capital Cube
Jun-07-17 04:01PM  REGENXBIO and AveXis Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector GlobeNewswire +6.15%
04:00PM  AveXis and REGENXBIO Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector GlobeNewswire
Jun-05-17 02:42PM  ETFs with exposure to REGENXBIO, Inc. : June 5, 2017 Capital Cube
Jun-02-17 09:50AM  REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-31-17 07:00AM  REGENXBIO Announces Initiation of Phase I Clinical Trial of RGX-314 Gene Therapy for Wet Age-Related Macular Degeneration GlobeNewswire
May-10-17 04:05PM  REGENXBIO to Present at the Bank of America Merrill Lynch 2017 Health Care Conference GlobeNewswire -7.92%
02:03AM  Edited Transcript of RGNX earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-09-17 06:36PM  Regenxbio reports 1Q loss Associated Press
04:01PM  REGENXBIO Reports First Quarter 2017 Financial Results and Recent Operational Highlights GlobeNewswire
01:30PM  Investor Network: REGENXBIO, Inc. to Host Earnings Call Accesswire
May-05-17 05:16PM  REGENXBIO, Inc. Value Analysis (NASDAQ:RGNX) : May 5, 2017 Capital Cube
May-04-17 04:07PM  Preclinical Data from REGENXBIO RGX-314 Gene Therapy Program for Wet Age-Related Macular Degeneration to be Presented at Upcoming Conferences GlobeNewswire
08:52AM  REGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : May 4, 2017 Capital Cube
May-02-17 04:05PM  REGENXBIO to Host Conference Call on May 9 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights GlobeNewswire -7.19%
Apr-26-17 04:01PM  REGENXBIO Announces Full Exercise and Closing of Underwriters Option to Purchase Additional Shares GlobeNewswire
Apr-05-17 08:23AM  REGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : April 5, 2017 Capital Cube
08:23AM  REGENXBIO, Inc. breached its 50 day moving average in a Bearish Manner : RGNX-US : April 5, 2017
Mar-31-17 08:15AM  Blog Coverage Jazz Pharmaceuticals Inks License Agreement with Nippon Shinyaku Accesswire
Mar-28-17 07:00AM  REGENXBIO Enhances and Expands Scientific Leadership GlobeNewswire
Mar-24-17 04:07PM  REGENXBIO INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-22-17 09:31AM  Regenxbio Leads Biotech Movers Ahead of Market's Open TheStreet.com -7.47%
09:31AM  Regenxbio Leads Biotech Movers Ahead of Market's Open
08:50AM  Regenxbio Sinks After Announcing Secondary Offering 24/7 Wall St.
08:50AM  Regenxbio Sinks After Announcing Secondary Offering
Mar-21-17 09:31PM  REGENXBIO Announces Pricing of Public Offering of Common Stock GlobeNewswire -8.30%
04:01PM  REGENXBIO Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-11-17 01:04PM  REGENXBIO INC. Financials
Mar-09-17 04:45PM  6 Stocks Trending Up With Big Volume TheStreet.com
04:45PM  6 Stocks Trending Up With Big Volume
10:53AM  REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017 Capital Cube
10:53AM  REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017
Mar-07-17 05:36PM  Regenxbio reports 4Q loss +6.11%
04:30PM  Regenxbio Inc Earnings Call scheduled for 4:30 pm ET today
04:12PM  REGENXBIO INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  REGENXBIO Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Operational Highlights GlobeNewswire
04:03PM  REGENXBIO Announces Initiation of Phase I/II Clinical Trial of RGX-501 for the Treatment of Homozygous Familial Hypercholesterolemia GlobeNewswire
07:07AM  Q4 2016 Regenxbio Inc Earnings Release - Before Market Open
Mar-06-17 04:05PM  REGENXBIO to Present at the Cowen and Company 37th Annual Health Care Conference GlobeNewswire
Feb-28-17 07:00AM  REGENXBIO to Host Conference Call on March 7 to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Operational Highlights GlobeNewswire
07:00AM  REGENXBIO Honors Rare Disease Day® 2017 GlobeNewswire
Feb-16-17 09:23AM  Rockville gene therapy company to begin trials for treatment for leading cause of blindness at bizjournals.com
Developing gene therapies for rare diseases with a proprietary delivery platform.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vasista VittalChief Financial OfficerJan 16Sale30.165,000150,800107,283Jan 18 04:17 PM
Mills Kenneth T.President and CEOJan 11Option Exercise0.85150,000127,500258,530Jan 16 04:17 PM
Vasista VittalChief Financial OfficerJan 05Option Exercise0.8530,00025,500112,283Jan 09 04:18 PM
Simpson CurranSVP, Technical OperationsDec 22Option Exercise22.0030,000660,00069,500Dec 27 04:17 PM
Simpson CurranSVP, Technical OperationsDec 22Sale33.0330,000990,90039,500Dec 27 04:17 PM
Mills Kenneth T.President and CEODec 20Sale31.7510,000317,500108,530Dec 21 04:15 PM
Vasista VittalChief Financial OfficerDec 19Sale30.004,994149,82082,283Dec 20 04:24 PM
Vasista VittalChief Financial OfficerDec 18Sale30.00618087,277Dec 20 04:24 PM
Simpson CurranSVP, Technical OperationsDec 07Option Exercise21.2321,890464,74061,390Dec 11 04:22 PM
Simpson CurranSVP, Technical OperationsDec 07Sale30.0421,890657,57639,500Dec 11 04:22 PM
Simpson CurranSVP, Technical OperationsDec 04Option Exercise13.091101,44039,610Dec 06 04:17 PM
Simpson CurranSVP, Technical OperationsDec 04Sale30.001103,30039,500Dec 06 04:17 PM
Simpson CurranSVP, Technical OperationsNov 27Option Exercise13.092,00026,18041,500Nov 29 04:30 PM
Simpson CurranSVP, Technical OperationsNov 27Sale29.312,00058,62039,500Nov 29 04:30 PM
Mills Kenneth T.President and CEONov 20Option Exercise0.8530,00025,500128,530Nov 21 04:18 PM
Mills Kenneth T.President and CEONov 20Sale27.7110,000277,100118,530Nov 21 04:18 PM
Vasista VittalChief Financial OfficerNov 15Sale25.305,000126,50087,283Nov 17 04:17 PM
Mills Kenneth T.President and CEOOct 20Sale32.6210,000326,18498,530Oct 24 04:18 PM
Vasista VittalChief Financial OfficerOct 16Sale33.255,000166,25092,283Oct 18 04:20 PM
HAYDEN DONALD J JRDirectorOct 11Option Exercise0.8520,00017,00020,000Oct 13 04:16 PM
HAYDEN DONALD J JRDirectorOct 11Sale34.9520,000699,0000Oct 13 04:16 PM
HAYDEN DONALD J JRDirectorSep 27Option Exercise0.8520,00017,00020,000Sep 29 04:19 PM
HAYDEN DONALD J JRDirectorSep 27Sale32.4520,000649,0000Sep 29 04:19 PM
Mills Kenneth T.President and CEOSep 20Sale29.3310,000293,273108,530Sep 22 04:17 PM
HAYDEN DONALD J JRDirectorSep 18Option Exercise0.8520,00017,00020,000Sep 19 04:20 PM
HAYDEN DONALD J JRDirectorSep 18Sale29.9520,000599,0000Sep 19 04:20 PM
HAYDEN DONALD J JRDirectorSep 15Option Exercise0.8520,00017,00020,000Sep 19 04:20 PM
HAYDEN DONALD J JRDirectorSep 15Sale27.4520,000549,0000Sep 19 04:20 PM
Vasista VittalChief Financial OfficerSep 15Sale27.395,000136,92597,283Sep 19 04:17 PM
Yoo StephenChief Medical OfficerSep 08Option Exercise0.8527,34223,24127,342Sep 12 04:17 PM
Yoo StephenChief Medical OfficerSep 08Sale25.0027,342683,5500Sep 12 04:17 PM
Yoo StephenChief Medical OfficerSep 06Option Exercise0.85855727855Sep 07 04:32 PM
Yoo StephenChief Medical OfficerSep 06Sale25.0085521,3750Sep 07 04:32 PM
Yoo StephenChief Medical OfficerSep 05Option Exercise0.8531,80327,03331,803Sep 07 04:32 PM
HAYDEN DONALD J JRDirectorSep 05Option Exercise0.8520,00017,00020,000Sep 07 05:37 PM
Yoo StephenChief Medical OfficerSep 05Sale25.0031,803795,0750Sep 07 04:32 PM
HAYDEN DONALD J JRDirectorSep 05Sale24.9520,000499,0000Sep 07 05:37 PM
Mills Kenneth T.President and CEOSep 05Sale25.0010,500262,500118,530Sep 07 04:29 PM
Mills Kenneth T.President and CEOAug 25Option Exercise0.8523,53020,001129,030Aug 29 04:23 PM
Yoo StephenChief Medical OfficerAug 21Option Exercise0.8515,00012,75015,000Aug 23 04:22 PM
Yoo StephenChief Medical OfficerAug 21Sale20.0315,000300,4500Aug 23 04:22 PM
Mills Kenneth T.President and CEOAug 21Sale20.056,500130,325105,500Aug 23 04:21 PM
Vasista VittalChief Financial OfficerAug 15Sale21.093,04064,111102,283Aug 17 04:19 PM
Yoo StephenChief Medical OfficerJul 20Option Exercise0.8515,00012,75015,000Jul 24 04:22 PM
Mills Kenneth T.President and CEOJul 20Sale18.666,500121,290112,000Jul 24 04:19 PM
Yoo StephenChief Medical OfficerJul 20Sale18.6615,000279,9000Jul 24 04:22 PM
Vasista VittalChief Financial OfficerJul 17Sale19.813,10061,411105,323Jul 19 04:22 PM
Yoo StephenChief Medical OfficerJun 20Option Exercise0.8515,00012,75015,000Jun 22 04:27 PM
Yoo StephenChief Medical OfficerJun 20Sale19.6815,000295,1570Jun 22 04:27 PM
Mills Kenneth T.President and CEOJun 20Sale19.686,500127,902118,500Jun 22 04:25 PM
Vasista VittalChief Financial OfficerJun 15Sale18.753,10058,125107,512Jun 19 04:16 PM
Vasista VittalChief Financial OfficerMay 15Sale19.073,10059,117110,612May 17 05:00 PM
HAYDEN DONALD J JRDirectorMay 15Sale19.048,599163,7250May 17 05:00 PM
HAYDEN DONALD J JRDirectorMay 08Sale18.3510,000183,5008,599May 10 05:00 PM
HAYDEN DONALD J JRDirectorMay 01Option Exercise0.8520,00017,00048,599May 03 05:00 PM
HAYDEN DONALD J JRDirectorMay 01Sale22.2630,000667,73618,599May 03 05:00 PM
Mills Kenneth T.President and CEOApr 24Sale20.9815,440323,955125,000Apr 26 09:02 PM
HAYDEN DONALD J JRDirectorApr 24Sale20.9810,000209,80028,599Apr 26 09:00 PM
Vasista VittalChief Financial OfficerApr 24Sale21.003,10065,099113,712Apr 26 09:00 PM